Author(s):
Sistla Mounica Prathyusha, Choppala Asha Deepti, Raghu Raj Naik, Mukthinuthalapati Mathrusri Annapurna
Email(s):
pratyushasistla07@gmail.com
DOI:
10.5958/0974-360X.2020.00248.6 
Address:
Sistla Mounica Prathyusha*, Choppala Asha Deepti, Raghu Raj Naik, Mukthinuthalapati Mathrusri Annapurna
GITAM Institute of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam-530045, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 3,
Year - 2020
ABSTRACT:
Selexipag is used for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Selexipag is a selective prostacyclin receptor agonist. Prostacyclin is a potent vasodilator with anti-proliferative, anti-inflammatory, and anti-thrombotic effects. New zero order and first derivative spectrophotometric methods have been proposed for the determination of Selexipag in pharmaceutical formulations. Selexipag obeys Beer-Lambert’s law over the concentration range 10-60 µg/ml for all the above mentioned methods and all the methods are validated as per ICH guidelines.
Cite this article:
Sistla Mounica Prathyusha, Choppala Asha Deepti, Raghu Raj Naik, Mukthinuthalapati Mathrusri Annapurna. Development and validated of spectrophotometric methods for the determination of Selexipag (An anti-hypertensive agent). Research J. Pharm. and Tech 2020; 13(3):1346-1350. doi: 10.5958/0974-360X.2020.00248.6
Cite(Electronic):
Sistla Mounica Prathyusha, Choppala Asha Deepti, Raghu Raj Naik, Mukthinuthalapati Mathrusri Annapurna. Development and validated of spectrophotometric methods for the determination of Selexipag (An anti-hypertensive agent). Research J. Pharm. and Tech 2020; 13(3):1346-1350. doi: 10.5958/0974-360X.2020.00248.6 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-3-53
REFERENCES:
1. Sitbon O and Morrell N. Pathways in pulmonary arterial hypertension: The future is here. European Respiratory Review. 2012; 21(126): 321-327.
2. Kotwal TS, Patwardhan DM, Amrutkar SS, Wagh MP. Development and validation of simple UV spectrophotometric method for the determination of Selexipag in API and its bulk dosage form. Indo American Journal of Pharmaceutical Research, 2017; 7(5): 8578-8586.
3. Giri Prasad Gorumutchu, Venkata Nadh Ratnakaram. Diazo coupling for the determination of Selexipag by visible spectrophotometry. International Journal of Green Pharmacy. 2018; 12(4): 822-828.
4. Giri Prasad Gorumutchu and Venkata Nadh Ratnakam. Oxidative coupling: A tranquil approach for determination of Selexipag by visible spectrophotometry. Oriental Journal of Chemistry, 2018; 34(6): 3112-3117.
5. Snigdha Damireddy, Pravalika K, Praveen M, Sathish G, Anusha M. Method development and validation of Selexipag in its bulk and dosage form by RP-HPLC. International Journal of Pharmacy and Biological Sciences. 2017; 7(4): 84-92.
6. ICH Q2 [R1] Validation of Analytical Procedures: Text and Methodology: November 2005.